"Protease Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).
| Descriptor ID |
D011480
|
| MeSH Number(s) |
D27.505.519.389.745
|
| Concept/Terms |
Protease Inhibitors- Protease Inhibitors
- Inhibitors, Protease
- Endopeptidase Inhibitors
- Inhibitors, Endopeptidase
- Protease Inhibitor
- Inhibitor, Protease
- Peptide Hydrolase Inhibitors
- Hydrolase Inhibitors, Peptide
- Inhibitors, Peptide Hydrolase
- Peptide Peptidohydrolase Inhibitors
- Inhibitors, Peptide Peptidohydrolase
- Peptidohydrolase Inhibitors, Peptide
- Protease Antagonists
- Antagonists, Protease
- Antiproteases
- Peptidase Inhibitors
- Inhibitors, Peptidase
|
Below are MeSH descriptors whose meaning is more general than "Protease Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protease Inhibitors".
This graph shows the total number of publications written about "Protease Inhibitors" by people in this website by year, and whether "Protease Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 1 | 1 | 2 |
| 1999 | 2 | 0 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 2 | 3 | 5 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 3 | 4 |
| 2007 | 0 | 3 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 4 | 5 |
| 2011 | 1 | 1 | 2 |
| 2012 | 2 | 0 | 2 |
| 2013 | 3 | 1 | 4 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2019 | 3 | 0 | 3 |
| 2020 | 1 | 0 | 1 |
| 2021 | 4 | 3 | 7 |
| 2022 | 1 | 3 | 4 |
| 2023 | 0 | 2 | 2 |
| 2025 | 1 | 0 | 1 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protease Inhibitors" by people in Profiles.
-
Tulane virus protease as a structural surrogate for inhibitor screening of human norovirus proteases. J Virol. 2026 03 24; 100(3):e0217625.
-
Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors. J Virol. 2025 02 25; 99(2):e0175724.
-
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. Sci Adv. 2023 03 29; 9(13):eade8778.
-
Chetomin, a SARS-CoV-2 3C-like Protease (3CLpro) Inhibitor: In Silico Screening, Enzyme Docking, Molecular Dynamics and Pharmacokinetics Analysis. Viruses. 2023 01 15; 15(1).
-
Global 5'-UTR RNA structure regulates translation of a SERPINA1 mRNA. Nucleic Acids Res. 2022 09 23; 50(17):9689-9704.
-
Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s. J Acquir Immune Defic Syndr. 2022 07 01; 90(3):343-350.
-
Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 Mpro/3CLpro in Living Cells. mBio. 2022 06 28; 13(3):e0078422.
-
Biochemical Screening of Potent Zika Virus Protease Inhibitors. ChemMedChem. 2022 04 20; 17(8):e202100695.
-
Norovirus Protease Structure and Antivirals Development. Viruses. 2021 10 14; 13(10).
-
DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 Mpro inhibitors. Proc Natl Acad Sci U S A. 2021 09 07; 118(36).